Evidence map›Paper›PMID 27178340›Full record

ArticleClinical and experimental medicine2017

High-resolution melting combines with Bayes discriminant analysis: a novel hepatitis C virus genotyping method.

Daxian Wu, Xiaoyu Fu, Ya Wen, Bingjie Liu, Zhongping Deng, Lizhong Dai, Deming Tan

Abstract readComparative StudyEvaluation Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Daxian WuDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Key Laboratory of Viral Hepatitis of Hunan Province, 87 Xiangya Road, Changsha, 410008, Hunan Province, China.
Xiaoyu FuDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Key Laboratory of Viral Hepatitis of Hunan Province, 87 Xiangya Road, Changsha, 410008, Hunan Province, China.
Ya WenDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Key Laboratory of Viral Hepatitis of Hunan Province, 87 Xiangya Road, Changsha, 410008, Hunan Province, China.
Bingjie LiuDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Key Laboratory of Viral Hepatitis of Hunan Province, 87 Xiangya Road, Changsha, 410008, Hunan Province, China.
Zhongping DengSansure Biotechnology Corporation, Changsha, Hunan, 410205, China.
Lizhong DaiSansure Biotechnology Corporation, Changsha, Hunan, 410205, China.
Deming TanDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Key Laboratory of Viral Hepatitis of Hunan Province, 87 Xiangya Road, Changsha, 410008, Hunan Province, China. dmt3008@163.com.
Xiangya Hospital Central South University · CNSansure Biotech (China) · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current hepatitis C virus (HCV) genotyping techniques are often highly technical, costly, or need improvements in sensitivity and specificity. These limitations indicate the need of novel methods for HCV genotyping. The present study aimed to develop a novel genotyping method combining high-resolution melting (HRM) analysis with Bayes discriminant analysis (BDA). Target gene fragment including 5'-untranslated and core region was selected. Four or five inner amplicons for every serum were amplified using nested PCR, HRM was used to determine the melting temperature of the amplicons, and HCV genotypes were then analyzed utilizing BDA. In initial genotyping (HCV genotypes were classified into 1b, 2a, 3a, 3b, and 6a), both the overall accuracy rate and the cross-validation accuracy rate were 92.6 %, external validation accuracy rate was 95.0 %. To enhance the accuracy rate of genotyping, HCV genotypes were firstly classified into 1b, 3a, 3b, and 2a-6a, followed by a supplementary genotyping for 2a-6a. Both the overall accuracy rate and the cross-validation accuracy rate reached 97.5 %, and external validation accuracy rate was 100 %. Comparing adjusted HRM genotyping with type-specific probe technique, the difference in accuracy rates was not significant. However, the limit of detection and cost were lower for HRM. Comparing with sequencing, the limit detection of HRM was the same as the former, but the cost of HRM was lower. Hence, HRM combined with BDA was a novel method that equipped with superior accuracy, high sensitivity, and lower cost and therefore could be a better technique for HCV genotyping.

Indexed as

Transition TemperatureCosts and Cost AnalysisDiscriminant AnalysisDNA, ViralGenotyping TechniquesHepacivirusHepatitis CHumansPolymerase Chain ReactionRNA, ViralSensitivity and SpecificityDNA, ViralRNA, ViralBayes discriminant analysisGenotypingHepatitis C virusHigh-resolution melting analysisSequencingType-specific probe

Identifiers

PMID27178340
OpenAlexW2376272368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.